166 related articles for article (PubMed ID: 32240528)
1. Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity.
Scalvenzi M; Cappello M; Costa C; Fabbrocini G; Luciano M; Villani A
Dermatol Ther (Heidelb); 2020 Jun; 10(3):465-468. PubMed ID: 32240528
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Efficacy of Vismodegib After its Withdrawal and Patients' Health-Related Quality of Life Using the Dermatology Life Quality Index (DLQI).
Villani A; Megna M; Fabbrocini G; Cappello M; Luciano MA; Costa C; Scalvenzi M
Dermatol Ther (Heidelb); 2019 Dec; 9(4):719-724. PubMed ID: 31506916
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
5. Real-Life Effectiveness of Vismodegib in Patients with Metastatic and Advanced Basal Cell Carcinoma: Characterization of Adverse Events and Assessment of Health-Related Quality of Life using the Dermatology Life Quality Index (DLQI) Test.
Villani A; Fabbrocini G; Cappello M; Costa C; Scalvenzi M
Dermatol Ther (Heidelb); 2019 Sep; 9(3):505-510. PubMed ID: 31165365
[TBL] [Abstract][Full Text] [Related]
6. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Sekulic A; Migden MR; Lewis K; Hainsworth JD; Solomon JA; Yoo S; Arron ST; Friedlander PA; Marmur E; Rudin CM; Chang AL; Dirix L; Hou J; Yue H; Hauschild A;
J Am Acad Dermatol; 2015 Jun; 72(6):1021-6.e8. PubMed ID: 25981002
[TBL] [Abstract][Full Text] [Related]
7. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
Bertrand N; Guerreschi P; Basset-Seguin N; Saiag P; Dupuy A; Dalac-Rat S; Dziwniel V; Depoortère C; Duhamel A; Mortier L
EClinicalMedicine; 2021 May; 35():100844. PubMed ID: 33997740
[TBL] [Abstract][Full Text] [Related]
8. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
10. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
Tong J; Mitchell B; Roth K; Logan D; Ernst S
J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
[TBL] [Abstract][Full Text] [Related]
11. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness.
Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K;
Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Real-Life Data, Efficacy and Safety of Vismodegib Treatment in Patients with Advanced and Multiple Basal Cell Carcinoma: 3-Year Experience from a Spanish Center.
Ayén-Rodríguez A; Linares-González L; Llamas-Segura C; Almazán-Fernández FM; Ruiz-Villaverde R
Int J Environ Res Public Health; 2023 May; 20(10):. PubMed ID: 37239551
[TBL] [Abstract][Full Text] [Related]
15. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
16. Treatment of basal cell carcinoma with vismodegib: future or present?
Velleman J; Kaarela O; Vranckx JJ
Acta Chir Belg; 2021 Jun; 121(3):198-203. PubMed ID: 31437079
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma.
Juzot C; Isvy-Joubert A; Khammari A; Knol AC; Nguyen JM; Dreno B
Eur J Dermatol; 2022 May; 32(3):401-407. PubMed ID: 36065537
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database.
Bassompierre A; Dalac S; Dreno B; Neidhardt EM; Maubec E; Capelle C; Andre F; Behal H; Dziwniel V; Bens G; Leccia MT; Meyer N; Granel-Brocard F; Beylot-Barry M; Dereure O; Basset-Seguin N; Mortier L
ESMO Open; 2021 Dec; 6(6):100284. PubMed ID: 34689002
[TBL] [Abstract][Full Text] [Related]
20. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma.
Sagiv O; Ding S; Ferrarotto R; Glisson B; Altan M; Johnson F; Elamin Y; Thakar SD; Nagarajan P; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2019; 35(4):350-353. PubMed ID: 30365473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
